Singapore-based healthtech unicorn Biofourmis raised an additional $20 million from Intel Capital Corp, the VC arm of chipmaker Intel. The startup will issue convertible Series D shares to the firm. With this investment, Biofourmis’ Series D funding reached $220 million.
_
This article has been summarised for quick read. You can find the original article on Deal Street Asia.